CELLDEX THERAPEUTICS INC stock forecast: down to 35.13 USD CLDX stock price prognosis
Forecast for Fri 28 Jan 2022 price
CELLDEX THERAPEUTICS INC stock price forecast for further price development down to -1.54% (time horizon: 1 day) and price target of 35.13 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) CELLDEX THERAPEUTICS INC share price prediction for 2022-01-28 with daily closed price projections
On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.
The forecast (dashed curve) of the share price performance is based on historical data.
Our forecast model is based on mathematical, statistical methods.
The website offers price forecasts and analysis tools for equities and other securities,
which are exclusively based on the prices of these securities in the past.
Information about these prices is provided to us by third parties. Although we believe,
If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and
correct sequencing of this information.
We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider
any financial data or other data of such issuers with the exception of the past prices of the securities.
Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or
that may be relevant for future security price flows. Investments require additional considerations.
Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor
or the tax implications an investment may have for the investor. Although we believe that
our mathematical models are a tool to try to explore the possibility for future price development
with the help of past performance, such developments are subject to a multitude of different influences.
and therefore not really predictable.
We cannot guarantee the success of any investment you make based on the information published here.
This website is for information purposes only. All information and data on this website cannot be guaranteed
to be accurate,
accuracy, completeness and appropriateness - neither explicit nor implicit.
Summerized Form 10-K with GPT-2
Currently, all programs are fully owned by Celldex. Consequently, there is a need for additional therapies. All patients will continue to be assessed for response through week 12. These patients all experienced complete responses. CDX-527 CDX-527 is the first candidate from Celldex's bispecific antibody platform. We also rely on CMOs for labeling and storage for studies outside the US. All products are then filled at CMOs. Clinical trials are generally conducted in three sequential phases. As a result, we do not know whether they are safe or effective for humans. Any such action could materially harm us. The FDA has agreed to specified performance goals in the review of NDAs and BLAs. Our website is located at http://www.celldex.com. 8203; • Risks related to managing our growth. We had an accumulated deficit of $1.1 billion as of December 31, 2020. We cannot be certain that we will achieve or sustain profitability in the future. We disagree with their objection and believe their objection to be without merit. Our drug candidates are subject to extensive regulatory scrutiny. Phase 2 testing generally lasts between 6 and 36 months. We face intense competition in our development activities. We have limited experience in commercial manufacturing. We may not realize the anticipated benefits of our acquisition of Kolltan. We also face the risk that others will infringe, avoid or circumvent our patents.
Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.
Meta analyst score 20.00/100
Institutional ownership list is based on filling form information
CELLDEX THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.
On-Balance Volume information for CELLDEX THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.
Accumulation / Distribution (A/D) indicator information for CELLDEX THERAPEUTICS INC. The indicator identify divergences between price and volume flow.
Aroon Oscillator information for CELLDEX THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.
Average Directional Index (ADX) information for CELLDEX THERAPEUTICS INC. The index can be used to identify the strengh of a trend.
Moving Average Convergence Divergence (MACD) for CELLDEX THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.
Stochastic Oscillator as momentum indicator for CELLDEX THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.
Relative Strength Index (RSI) for CELLDEX THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development.
The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period.
Primary usage of the indicator is to identify overbought or oversold signals.
When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30
Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio